Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety and Efficacy of Interventional Ablation for High-risk Pulmonary Nodules or Early-stage Lung Cancer: A Multicenter, Prospective, Real-World Study

NCT07005999 is registered in ClinicalTrials.gov with Guangzhou Institute of Respiratory Disease as lead sponsor.

NCT NCT07005999
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07005999 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety and Efficacy of Interventional Ablation for High-risk Pulmonary Nodules or Early-stage Lung Cancer: A Multicenter, Prospective, Real-World Study
Lead sponsor
Guangzhou Institute of Respiratory Disease
Phase
Observational
Overall status
Active, not recruiting
Start date
April 12, 2025
Completion date
December 31, 2028
Enrollment
656 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

early stage lung non-small cell carcinoma, lung cancer (nsclc)